Experimental radiation drug enters first human tests for tough thyroid cancers
NCT ID NCT07287748
First seen Jan 09, 2026 · Last updated Apr 22, 2026 · Updated 12 times
Summary
This is the first study in people testing a new drug called Af-001 for advanced thyroid cancer that has returned or spread after surgery and standard treatments. The first part checks the safety and best dose of a single injection. The second part tests multiple injections to see if the drug can shrink tumors in patients who haven't had a common radioactive iodine treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DTC - DIFFERENTIATED THYROID CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Cancer Center Hospital East
RECRUITINGKashiwa, Japan
Conditions
Explore the condition pages connected to this study.